Communiqués

Release
31.10.2019

VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French)

Download
Release
10.10.2019

VALBIOTIS launches a share capital increase with Shareholders’ Preferential Subscription Rights (in French)

Download
Release
16.09.2019

VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, at EASD 2019

Download
Release
02.09.2019

Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension

Download
Release
30.08.2019

2019 half-year report and update on key achievements (in French)

Download
Release
01.08.2019

Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)

Download
Release
26.07.2019

Half year report of the liquidity contract – July 2019 (in French)

Download
Release
03.07.2019

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes

Download
Release
24.06.2019

VALBIOTIS participates in the first HealthTech Investor Days, organized by France Biotech

Download